Second?generation tyrosine kinase inhibitors in chronic myelogenous leukemia

Posted by rob on October 30, 2010 under Uncategorized | Comments are off for this article

Imatinib should continue to be the front?line therapy for patients who have newly diagnosed chronic myelogenous leukemia accompanied by close monitoring. Patients should switch to a second?generation tyrosine kinase inhibitor at the earliest sign of resistance or suboptimal response to imatinib. (Source: Cancer)
More